

10-26-2017

Dabigatran Reversal with Idarucizumab.

Charles V. Pollack

Thomas Jefferson University, Philadelphia, PA, United States, Charles.Pollack@jefferson.edu

Paul A Reilly

Boehringer Ingelheim, Ridgefield, CT, United States

Jeffrey I Weitz

McMaster University, Hamilton, ON, Canada

Let us know how access to this document benefits you

Follow this and additional works at: <https://jdc.jefferson.edu/medfp> Part of the [Other Medical Specialties Commons](#)

Recommended Citation

Pollack, Charles V.; Reilly, Paul A; and Weitz, Jeffrey I, "Dabigatran Reversal with Idarucizumab."
(2017). *Department of Medicine Faculty Papers*. Paper 223.<https://jdc.jefferson.edu/medfp/223>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

and their skill level, and a possible tendency to be selected on a team to allow a more flexible strategy.⁴ We speculate that players who throw right-handed and bat left-handed enjoy an additional biomechanical advantage, with the dominant (throwing) hand being placed further from the hitting end of the bat, providing a longer lever with which to hit the ball (potentially at the expense of bat control⁵). Given these sport-specific explanations, our findings argue against any advantage due to hemispheric lateralization.

David L. Mann, Ph.D.

Vrije Universiteit Amsterdam
Amsterdam, the Netherlands

Florian Loffing, Ph.D.

University of Oldenburg
Oldenburg, Germany

Peter M. Allen, Ph.D.

Anglia Ruskin University
Cambridge, United Kingdom
peter.allen@anglia.ac.uk

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

1. Hécaen H, Sauguet J. Cerebral dominance in left-handed subjects. *Cortex* 1971;7:19-48.
2. McLean JM, Ciurczak FM. Bimanual dexterity in major league baseball players: a statistical study. *N Engl J Med* 1982;307:1278-9.
3. Grondin S, Guiard Y, Ivry RB, Koren S. Manual laterality and hitting performance in Major League Baseball. *J Exp Psychol Hum Percept Perform* 1999;25:747-54.
4. Brooks R, Bussière LF, Jennions MD, Hunt J. Sinister strategies succeed at the cricket World Cup. *Proc Biol Sci* 2004;271: Suppl 3:S64-S66.
5. Mann DL, Runswick OR, Allen PM. Hand and eye dominance in sport: are cricket batters taught to bat back-to-front? *Sports Med* 2016;46:1355-63.

DOI: 10.1056/NEJMc1711659

Dabigatran Reversal with Idarucizumab

TO THE EDITOR: Data provided by Pollack and colleagues (Aug. 3 issue)¹ suggest a dissociation between the normalization of the coagulation profile and the establishment of effective hemostasis after the administration of idarucizumab in patients with uncontrolled bleeding. The median time to the cessation of bleeding was 2.5 hours among patients with nonintracranial hemorrhage. In analyses reported separately, the median time to the cessation of bleeding was 3.5 hours among patients with gastrointestinal bleeding and 4.5 hours among those with nonintracranial and nongastrointestinal bleeding.² The median time to the cessation of bleeding was 11.4 hours when intracranial hemorrhage was included in the analysis involving patients with serious bleeding.³ Should clinicians rely solely on idarucizumab and hope that their patients do not die from uncontrolled hemorrhage while waiting for hemostasis to be established? A reasonable approach would be to administer blood-component therapy (e.g., prothrombin complex concentrate and activated prothrombin complex concentrate) — a bridge between the normalization of the coagulation profile and the establishment of hemostasis, according to *in vitro* and preclinical data^{4,5} — in addition to idarucizumab. It can be reasonably argued that the establishment of effective hemostasis with blood-component and idarucizumab therapy outweighs the risk of thrombotic adverse events among patients with serious hemorrhaging. The

effectiveness and need for further blood-component and idarucizumab therapy may be assessed by serial clinical assessments and a serial profile of clotting times.

Luke Yip, M.D.

Rocky Mountain Poison and Drug Center
Denver, CO
luke.yip@rmpdc.org

Jou-Fang Deng, M.D.

Taipei Veterans General Hospital
Taipei, Taiwan

No potential conflict of interest relevant to this letter was reported.

1. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. *N Engl J Med* 2017; 377:431-41.
2. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD study. Presented at the 2016 American Heart Association Scientific Sessions, New Orleans, November 12–16, 2016 (https://professional.heart.org/lidc/groups/ahamam-public/@wcm/@sop/@scon/documents/downloadable/ucm_489916.pdf).
3. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. *N Engl J Med* 2015;373:511-20.
4. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. *Stroke* 2011;42:3594-9.
5. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. *J Thromb Thrombolysis* 2015;39:395-402.

DOI: 10.1056/NEJMc1711337

TO THE EDITOR: In 2015, an interim analysis involving 51 patients with acute bleeding who had

received idarucizumab for dabigatran reversal was published in the *Journal*.¹ That article reported a median time to the cessation of bleeding of 11.4 hours among 35 of 51 patients (69%). At a 2016 American Heart Association conference, data from 298 patients with acute bleeding were presented. The median time to the cessation of bleeding was reported in 158 patients (53%) as 3.5 hours among 97 patients with gastrointestinal bleeding and as 4.5 hours among 61 patients with nongastrointestinal and nonintracranial bleeding.² Finally, in the full cohort analysis involving 503 patients, of the 301 patients with acute bleeding, the median time to the cessation of bleeding is reported as 2.5 hours but was analyzed in only 134 patients (45%).

We are concerned that selective reporting bias influenced the reporting of this important secondary clinical outcome, because each subsequent analysis reduced the fraction of the cohort included in this calculation (from 69% to 53% to 45%) while increasing the apparent clinical efficacy. We ask the authors to provide substantially more robust reporting of these data for the full cohort to better illuminate these evolving results.

Ryan P. Radecki, M.D.

University of Texas Health Science Center at Houston
Houston, TX

Thomas G. DeLoughery, M.D.

Oregon Health and Science University
Portland, OR
delought@ohsu.edu

No potential conflict of interest relevant to this letter was reported.

1. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. *N Engl J Med* 2015;373:511-20.
2. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD study. Presented at the 2016 American Heart Association Scientific Sessions, New Orleans, November 12-16, 2016 (https://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_489916.pdf).

DOI: 10.1056/NEJMc1711337

TO THE EDITOR: Pollack et al. report the anticipated final results of the RE-VERSE AD study regarding the use of idarucizumab to reverse the effects of dabigatran in patients who have life-threatening hemorrhage or who are undergoing emergency surgery. However, the authors do not report the correlation between the activated partial-thromboplastin time (aPTT) and the diluted thrombin time, the ecarin clotting time, or dabi-

gatan concentration. There is some evidence,^{1,2} and some degree of consensus,³ that the aPTT (the only measurement available in emergency situations in most centers) is too insensitive to estimate dabigatran concentration, but little of the evidence has been gathered in the context of urgent reversal and not in a prespecified peak-trough fashion. Therefore, an analysis of this correlation in the more than 500 patients who were included in the RE-VERSE AD study would be valuable. Given that urgent reversal is a rare need, this information is not likely to be obtained otherwise. Were the aPTT results not reported or analyzed because of the already available evidence that aPTT should not be used? Would the authors provide sensitivity and specificity and predictive values for aPTT to detect therapeutic dabigatran concentrations?

Marc Sorigue, M.D.

Institut Català d'Oncologia
Badalona, Spain
msorigue@iconcologia.net

No potential conflict of interest relevant to this letter was reported.

1. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. *Chest* 2017;151:127-38.
2. Ebner M, Birschmann I, Peter A, et al. Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. *Stroke* 2017;48:2457-63.
3. Ageno W, Büller HR, Falanga A, et al. Managing reversal of direct oral anticoagulants in emergency situations: Anticoagulation Education Task Force White Paper. *Thromb Haemost* 2016;116:1003-10.

DOI: 10.1056/NEJMc1711337

THE AUTHORS REPLY: Idarucizumab is licensed for dabigatran reversal in patients who have serious bleeding or are undergoing urgent surgery. Yip and Deng speculate that in addition to idarucizumab, prohemostatic agents such as prothrombin complex concentrate or recombinant activated factor VII should be administered to hasten hemostasis in dabigatran-treated patients with severe hemorrhage. Few of the patients who were enrolled in the RE-VERSE AD study received prohemostatic agents in addition to idarucizumab, so the efficacy and safety of such therapy cannot be assessed.¹ However, prohemostatic agents are unlikely to be of benefit unless there is associated coagulopathy, because idarucizumab reverses the anticoagulant effects of dabigatran within minutes. Furthermore, prohemostatic agents may increase the risk of thrombosis.

Radecki and DeLoughery are concerned about the divergence in the median times to the cessation of bleeding that were reported in the interim and final analyses of the data from the RE-VERSE AD study. For patients with serious bleeding, the protocol mandated the assessment of the time to the cessation of bleeding up to 24 hours after the administration of the first vial of idarucizumab.¹ The longer time that was reported in the interim analyses^{2,3} reflects the inclusion of patients with recorded times exceeding 24 hours and patients with intracranial hemorrhage, many of whom did not undergo repeat brain imaging until several days after admission. To adhere to the per-protocol definition, these patients were excluded in the final analysis, which explains the shorter times to the cessation of bleeding. We agree that their exclusion limits the generalizability of the findings to this subgroup. Therefore, postmarketing data are needed to better assess the effect of idarucizumab on the time to the cessation of bleeding in these patients.⁴

Sorigue correctly points out that the diluted thrombin time or ecarin clotting time is not available in many hospitals, and he requests information on the correlation between the aPTT and these tests. This information is provided in Figure 1D of our article and in Figure S2 in the Supplementary Appendix (available with the full text of our article at NEJM.org), which show that there is good correlation between the aPTT as measured in the central laboratory and the more specialized tests. Therefore, these data provide preliminary evidence that the aPTT can also be used to monitor dabigatran reversal, provided

that the test is performed with a reagent that is sensitive to the anticoagulant effects of dabigatran. In the RE-VERSE AD study, the central laboratory used the CK-Prest reagent (Diagnostica Stago). It is important to point out, however, that coagulation testing before the administration of idarucizumab is not essential in patients who have life-threatening bleeding or in whom urgent surgery is indicated.

Charles V. Pollack, Jr., M.D.

Thomas Jefferson University
Philadelphia, PA
charles.pollack@jefferson.edu

Paul A. Reilly, Ph.D.

Boehringer Ingelheim
Ridgefield, CT

Jeffrey I. Weitz, M.D.

McMaster University
Hamilton, ON, Canada

Since publication of their article, the authors report no further potential conflict of interest.

1. Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. *Thromb Haemost* 2015;114:198-205.

2. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. *N Engl J Med* 2015;373:511-20.

3. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD Study. Presented at the 2016 American Heart Association Scientific Sessions, New Orleans, November 12–16, 2016 (https://professional.heart.org/idc/groups/ahamam-public/@wcm/@sop/@scon/documents/downloadable/ucm_489916.pdf).

4. Kermer P, Eschenfelder CC, Diener H-C, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany — a national case collection. *Int J Stroke* 2017;12:383-91.

DOI: 10.1056/NEJMc1711337

IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation

TO THE EDITOR: The study conducted by Jordan et al. (Aug. 3 issue)¹ included a low-risk population (2 patients did not have donor-specific antibodies) and pretreatment class I donor-specific antibody levels (the major risk factor for antibody-mediated rejection) were modest (mean [±SD] fluorescence intensity, 5660±2364), yet a high rate of rejection occurred (10 of 22 patients [45%] with donor-specific antibodies). These data raise serious concerns for higher-risk patients.

A high rate of delayed graft function (77% of patients) occurred in the U.S. cohort, despite a short cold ischemia time (mean, 19.9±5.2 hours). Did kidney biopsies that were performed in patients with delayed graft function reveal endothelial or renal tubular injury? Since donor-specific antibodies induce pathogenic signaling properties in endothelium,² it is important to determine whether F(ab')₂ donor-specific antibody fragments retain signaling properties, particularly if